Literature DB >> 12970276

Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.

Leon J S Brokken1, Wilmar M Wiersinga, Mark F Prummel.   

Abstract

Antithyroid treatment effectively restores euthyroidism in patients with Graves' hyperthyroidism. After a few months of treatment, patients are clinically euthyroid with normal levels of thyroid hormones, but in many patients TSH levels remain suppressed. We postulated that TSH receptor autoantibodies could directly suppress TSH secretion, independently from thyroid hormone levels, via binding to the pituitary TSH receptor. To test this hypothesis, we prospectively followed 45 patients with Graves' hyperthyroidism who were treated with antithyroid drugs. Three months after reaching euthyroidism, blood was drawn for the analysis of thyroid hormones, TSH, and TSH binding inhibitory Ig (TBII) levels. After 6.7 +/- 1.5 months since start of antithyroid treatment, 20 patients still had detectable TBII levels, and 25 had become TBII negative. The two groups had similar levels of free T(4) and T(3), but TBII-positive patients had lower TSH values than TBII-negative patients: median 0.09 (range < 0.01-4.30) mU/liter vs. 0.84 (0.01-4.20; P = 0.015). In addition, TSH levels correlated only with TBII titers (r = -0.424; P = 0.004), and not with free T(4) or T(3) values. Our findings suggest that TBII suppress TSH secretion independently of thyroid hormone levels, most likely by binding to the pituitary TSH receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970276     DOI: 10.1210/jc.2003-030430

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Relationship between thyroid stimulating hormone and thyroid stimulating immunoglobulin in Graves' hyperthyroidism.

Authors:  K A Woeber
Journal:  J Endocrinol Invest       Date:  2010-09-17       Impact factor: 4.256

2.  Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.

Authors:  T Majima; Y Komatsu; K Doi; C Takagi; M Shigemoto; A Fukao; T Morimoto; J Corners; K Nakao
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

3.  Energy Homeostasis and Body Weight before and after Cessation of Block and Replacement Therapy in Euthyroid Patients with Graves' Disease.

Authors:  Lars P Klieverik; Andries Kalsbeek; Mariëtte T Ackermans; Hans P Sauerwein; Wilmar M Wiersinga; Eric Fliers
Journal:  Int J Endocrinol       Date:  2011-11-29       Impact factor: 3.257

4.  Agoitrous Graves' Hyperthyroidism with Markedly Elevated Thyroid Stimulating Immunoglobulin Titre displaying Rapid Response to Carbimazole with Discordant Thyroid Function.

Authors:  Yin Chian Kon; Brenda Su Ping Lim; Yingshan Lee; Swee Eng Aw; Yoko Kin Yoke Wong
Journal:  J ASEAN Fed Endocr Soc       Date:  2020-11-19

5.  Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide.

Authors:  Claire L Wood; Niamh Morrison; Michael Cole; Malcolm Donaldson; David B Dunger; Ruth Wood; Simon H S Pearce; Timothy D Cheetham
Journal:  Eur Thyroid J       Date:  2022-01-01

6.  TSH and Thyrotropic Agonists: Key Actors in Thyroid Homeostasis.

Authors:  Johannes W Dietrich; Gabi Landgrafe; Elisavet H Fotiadou
Journal:  J Thyroid Res       Date:  2012-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.